David Shaw’s LENZ Therapeutics LENZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$718K Buy
+187,027
New +$931K ﹤0.01% 4040
2025
Q1
– Sell
-7,447
Closed -$215K – 4827
2024
Q4
$215K Buy
+7,447
New +$227K ﹤0.01% 4053
2023
Q4
– Sell
-6,775
Closed -$118K – 4674
2023
Q3
$118K Buy
6,775
+1,077
+19% +$18.7K ﹤0.01% 3840
2023
Q2
$104K Buy
5,698
+1,357
+31% +$27.1K ﹤0.01% 3828
2023
Q1
$74.4K Buy
4,341
+15
+0.3% +$243 ﹤0.01% 4004
2022
Q4
$101K Hold
4,326
– – ﹤0.01% 4363
2022
Q3
$96K Sell
4,326
-2,395
-36% -$57.1K ﹤0.01% 4602
2022
Q2
$129K Buy
+6,721
New +$150K ﹤0.01% 4676
2021
Q4
– Sell
-7,639
Closed -$876K – 5764
2021
Q3
$876K Buy
+7,639
New +$1.13M ﹤0.01% 3712

Other funds holding LENZ

David Shaw's LENZ Position: Q3 2026 in Review

David Shaw opened a new position in LENZ Therapeutics (LENZ) in Q3 2026: 187,027 shares worth $718K. The stake represents ﹤0.01% of the portfolio and ranks #4040 among its holdings. This is a return to the name: David Shaw previously reported a position in LENZ as recently as Q4 2024.

David Shaw first reported a position in LENZ in Q3 2021 and has held it in 9 quarters since. The position peaked at $876K in Q3 2021. 138 funds tracked by Wall St. Rank hold LENZ as of Q3 2026.

  • David Shaw held 187,027 shares of LENZ Therapeutics worth $718K as of Q3 2026.
  • LENZ Therapeutics was a new David Shaw position in Q3 2026.
  • LENZ Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q3 2026, its #4040 holding.
  • David Shaw first reported a position in LENZ Therapeutics in Q3 2021 and has held it in 9 quarters since.
  • David Shaw's LENZ Therapeutics position peaked at $876K in Q3 2021.
  • 138 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2026.

Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.